NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) —
WHY: Rosen Regulation Company, a world investor rights legislation company, reminds clients of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the necessary April 14, 2026 lead plaintiff time limit.
SO WHAT: For those who bought REGENXBIO securities all through the Elegance Length you can be entitled to repayment with out fee of any out of pocket charges or prices via a contingency charge association.
WHY ROSEN LAW: We inspire traders to make a choice certified suggest with a observe report of luck in management roles. Incessantly, corporations issuing notices shouldn’t have similar enjoy, sources, or any significant peer popularity. Many of those corporations don’t in reality deal with securities elegance movements, however are simply middlemen that refer purchasers or spouse with legislation corporations that in reality litigate the instances. Be smart in deciding on suggest. The Rosen Regulation Company represents traders all over the globe, concentrating its observe in securities elegance movements and shareholder spinoff litigation. Rosen Regulation Company has completed, at the moment, the biggest ever securities elegance motion agreement in opposition to a Chinese language Corporate. Rosen Regulation Company was once Ranked No. 1 by means of ISS Securities Elegance Motion Products and services for choice of securities elegance motion settlements in 2017. The company has been ranked within the best 4 each and every 12 months since 2013 and has recovered masses of thousands and thousands of greenbacks for traders. In 2019 by myself the company secured over $438 million for traders. In 2020, founding spouse Laurence Rosen was once named by means of law360 as a Titan of Plaintiffs’ Bar. Most of the company’s legal professionals were identified by means of Lawdragon and Tremendous Legal professionals.
DETAILS OF THE CASE: Consistent with the lawsuit, defendants supplied traders with subject material data relating to REGENXBIO’s plan to increase and commercialize its product candidate RGX-111, a one-time gene treatment for the remedy of critical Mucopolysaccharidosis Sort I, often referred to as Hurler syndrome. Defendants’ statements incorporated, amongst different issues, REGENXBIO’s sure assertions of RGX-111’s long run trial luck in keeping with proceeding sure biomarker and protection knowledge from the continuing PhaseI/II find out about. Defendants supplied those overwhelmingly sure statements to traders whilst, on the similar time, disseminating false and deceptive statements and/or concealing subject material opposed info regarding the efficacy and protection of its RGX-111 trial find out about. When the real main points entered the marketplace, the lawsuit claims that traders suffered damages.
No Elegance Has Been Qualified. Till a category is qualified, you don’t seem to be represented by means of suggest until you keep one. Chances are you’ll make a choice suggest of your selection. You might also stay an absent elegance member and do not anything at this level. An investor’s talent to percentage in any doable long run restoration isn’t dependent upon serving as lead plaintiff.
Lawyer Promoting. Prior effects don’t ensure a an identical result.
——————————-
Touch Data:
